🏆 La Cámara Peruana de Comercio Exterior OFICIAL desde 2011 • ENIEX • Member of Internationally United Commercial Agents and Brokers • Google Workspace School • +40,000 alumnos certificados Conoce nuestra historia
0Contactanos
by Soporte CamexFDA
Live Briefing · Sem.6 día 2 Vol. I · Núm. 032
MAR · 23.JUN.2026 Lima — Perú 07:45 UTC-5
C
CAMEX  ·  FDA SERVICES DIVISION
FDA Briefing
Diario.

Edición № 032. Sem.6 día 2 · Safety Substantiation deep-dive. Section 608 de MoCRA mandates que responsible person “ensure y maintain records supporting adequate substantiation of safety” para cada cosmetic product en mercado. 3+ años después de MoCRA enacted, FDA aún no ha emitido guidelines específicas interpretando “adequate substantiation”. El vacuum interpretativo crea exposure asimétrico — particularmente para LatAm exporters. Hoy: framework + 6 pillars + records access power + high-risk ingredients + 5 gaps comunes LatAm.

Edición
№ 032
CoberturaSafety Substantiation
FocoSection 608 deep-dive
FormatoDoctrine + actionable
Próxima edición24.JUN.2026
Sem.6 · día 2 · the underrated obligation

El renewal countdown (8 días) sigue activo — sin embargo, hoy pivotamos a la obligation MoCRA más subestimada: safety substantiation. A diferencia de facility registration (deadline-based, visible) y product listing (form-based, structured), safety substantiation es continuous obligation sin guidance interpretativa. Cada producto en mercado USA requires it. La mayoría de LatAm cosmetics manufacturers tienen gaps materiales en este aspecto — gaps que FDA puede now access durante inspections vía Section 610 records access power.

U.S. FDA · MoCRA Section 608 · Safety Substantiation · Records Access Authority SECTION 608
Obligation
Section 608 · continuous
FDA Guidance
3+ años · sin interpretación
Records Access
Section 610 · inspections
LatAm exposure
Asimétrica · gap structural
Safety substantiation · Section 608 · doctrine deep-dive

La obligation MoCRA que nadie ve · hasta que FDA pide records.

Section 608 de MoCRA establece que el responsible person “shall ensure, and maintain records supporting, that there is adequate substantiation of safety of such cosmetic product”. La definición legal está ahí — pero FDA aún no ha emitido guidance interpretativa después de 3+ años. ¿Qué significa “adequate”? ¿Qué tipo de records? ¿Por cuánto tiempo? ¿Qué formato? ¿Qué tests son required? El vacuum interpretativo es structural, no incidental. Cada manufacturer interpreta independently — y FDA inspectores aplican judgment case-by-case during inspections.

Lo crítico operativamente: FDA tiene records access power amplificado bajo MoCRA. Bajo Section 605, durante inspections FDA puede access adverse event report records. Bajo Section 610, FDA puede access y copy records when has “reasonable belief that a cosmetic product is likely adulterated and that use or exposure presents a threat of serious adverse health consequences or death”. FDA’s January 2026 draft guidance specifically clarified que safety substantiation records están entre los accessibles. Sin substantiation records adequate, durante inspection tu facility está effectively undefended. Para LatAm exporters: la combinación de (α) vacuum interpretativo + (β) records access power + (γ) increased FDA inspection activity = exposure asimétrico particularly punishing para foreign manufacturers que no tienen access directa a FDA culture interpretiva.

608
section MoCRA
safety substantiation
3+
años sin FDA guidance
interpretativa específica
610
section MoCRA
records access power
6
pillars de evidence
standard de industria

Las 5 noticias Section 608 del día

Selección Camex · Curado 23.JUN.2026 · 07:30
01Framework
MoCRA Section 608 Adequate substantiation Sin guidance · 3 años

Section 608: la obligation sin definición operativa.

Section 608 está estructuralmente clara en su requirement: responsible person must ensure and maintain records supporting adequate safety substantiation. Pero el adjetivo “adequate” es donde el problema operativo emerge. ¿Adequate según qué standard? ¿Cosmetic ingredient safety standards (CIR)? ¿European Cosmetic Regulation (EC 1223/2009) safety assessment framework? ¿FDA’s pre-existing guidance documents on specific ingredients? ¿Academic consensus? FDA no ha indicated cuál. La industria operates en interpretive ambiguity.

Industry practice ha gradualmente convergido en 6 pillars de evidence typically expected: (α) toxicological data per ingredient — typically from CIR Expert Panel reports, RIFM data para fragrance, ECETOC data para EU markets; (β) stability testing — accelerated + real-time stability del finished product; (γ) microbial testing — challenge testing + preservative efficacy testing; (δ) compatibility testing — ingredient interactions + packaging compatibility; (ε) safety assessment — typically formal CPSR (Cosmetic Product Safety Report) by qualified safety assessor; (ζ) intended use evaluation — exposure assessment based en typical use patterns. Sin estos 6 pillars documented, gap structural exists. Para LatAm: muchos manufacturers tienen 2-4 de los 6, no los 6 completos.

“FDA no ha definido ‘adequate’. Industry ha convergido en 6 pillars. La mayoría LatAm operates con 2-4 pillars documented. El gap es structural, exposed durante inspections.” — Camex · doctrina 6 pillars
▲ Impacto LatAm

LatAm cosmetics manufacturers — particularly SME + natural/botanical ingredient operators — typically tienen partial substantiation: ingredient toxicological data via supplier COAs (pillar α partial), some stability testing (pillar β partial), basic microbial (pillar γ partial). Less común: formal CPSR (pillar ε), comprehensive intended use evaluation (pillar ζ). Gap typically 2-3 pillars. Durante FDA inspection, gap is structurally exposed.

✓ Acción Camex recomendada

Safety substantiation gap assessment para LatAm cosmetics facility: audit existing documentation contra los 6 pillars. Identify gaps. Prioritize por product (high-volume products first, high-risk ingredients products first). Implement gap closure en 6-12 meses. Investment $5K-50K per product line dependiendo del scope. Camex articula gap assessment + closure framework específico.

Fuente: MoCRA Section 608 · 21 USC §364c · industry best practices · CIR Expert Panel · CPSR framework

6 pillars · evidence framework
INDUSTRY-CONVERGED STANDARD α · TOXICOLOGICAL DATA CIR · RIFM · ECETOC per ingredient β · STABILITY TESTING Accelerated + real-time stability γ · MICROBIAL TESTING Challenge + preservative efficacy δ · COMPATIBILITY Ingredient + packaging interactions ε · CPSR ★ Formal safety assessment qualified ζ · INTENDED USE Exposure assessment patterns PILLAR ε ES THE WEAK LINK LATAM
6 pillars converged industry standard. Pillar ε (CPSR formal safety assessment) es typically el weakest entre LatAm manufacturers — gap más comúnmente exposed.
02Records access
Section 605 + 610 Draft guidance ENE 2026 Inspection authority

Section 605 + 610: FDA can access tus substantiation records.

MoCRA dio a FDA amplified records access power que no existía pre-MoCRA. Bajo Section 605, FDA may access adverse event report records durante routine inspections. Bajo Section 610, FDA may access y copy records cuando tiene “reasonable belief that a cosmetic product is likely adulterated y that use or exposure presents a threat of serious adverse health consequences or death”. La January 2026 FDA draft guidance specifically clarified que safety substantiation records están entre los accessibles bajo Section 610.

La draft guidance enero 2026 incluye lista específica de records que FDA puede access: manufacturing records, raw material receipt records, product distribution records, analytical results, recall records, customer distribution lists, complaint records, y safety substantiation records. Esta es lista broad — covering basically toda la operational documentation. Para LatAm exporters, esto crea exposure asimétrica: foreign facilities subject to FDA inspection (when imported product is allegedly involved), con records access powers que no existían pre-MoCRA. Trinity required: (α) records exist physically/digitally, (β) records are accessible during inspection, (γ) records are interpretable by FDA inspector. Sin todos los 3, technical compliance fails durante inspection.

“FDA can access safety substantiation records when reasonable belief de adulteration. La January 2026 guidance específicamente clarifies — no es ‘we might’, es ‘we will’. Foreign facilities están dentro del scope.” — Camex · doctrina records access
▲ Impacto LatAm

LatAm cosmetics manufacturers sin systematized safety substantiation documentation system: during FDA inspection (foreign facility o via FSVP-triggered review), records request es predictible. Si tu organization no puede produce los records dentro de 24-48 horas (typical FDA expectation), el outcome es treated como gap structural — same operational consequence que not having records at all. Asunción que “we have it somewhere” not protective. Sistematización + accessibility son required components, no add-ons.

✓ Acción Camex recomendada

Records system audit para LatAm cosmetics: (α) confirm safety substantiation records exist por product, (β) centralize records en accessible digital system (no scattered en email, paper files, multiple desktops), (γ) implement search/retrieval capability under 30 min, (δ) prepare bilingual documentation summary (English-Spanish/Portuguese) para FDA inspector accessibility, (ε) annual mock records audit. Camex provee records system framework específico.

Fuente: MoCRA Section 605 + 610 · FDA January 2026 Draft Guidance Records Access · 21 CFR §700 · SafetyCall analysis

Section 605 vs 610 · access powers comparativos
FDA RECORDS ACCESS AUTHORITY SECTION 605 605 Routine inspection Adverse event records Narrower scope Standard authority Pre-existing parallel food/drug systems SECTION 610 ★ 610 Adulteration belief BROAD scope Includes safety substantiation + manufacturing + distribution TRIGGER 610 “Reasonable belief · likely adulterated · serious adverse health consequences or death”
Section 610 es el power amplified — broad access incluyendo safety substantiation records. Trigger: reasonable belief de likely adulteration + serious threat.
03Mandatory recall
Draft guidance DEC 2025 Mandatory recall authority Parallel framework

Mandatory recalls · Draft Guidance DEC 2025 · framework paralelo.

El 18 de diciembre de 2025, FDA emitió Draft Guidance “Questions and Answers Regarding Mandatory Cosmetics Recalls”. Pre-MoCRA, FDA podía solo request voluntary recalls de cosmetics — sin mandatory authority. MoCRA cambió esto: FDA ahora puede order mandatory recall cuando reasonable belief de adulteration + serious adverse health consequences. La draft guidance explica how FDA decidirá when mandatory recall is warranted, the process de implementation, y expectations para industry cooperation + communication.

El framework operativo: FDA mandatory recall power + records access power + safety substantiation requirement operan en tríada coordinada. La cadena lógica: (α) adverse event reported triggers attention, (β) FDA initiates inspection or records request, (γ) safety substantiation records reviewed, (δ) if gaps identified + adulteration belief reasonable, mandatory recall ordered, (ε) records access power supports investigation. Cada una de las tres powers reinforces las otras dos. Para LatAm: el mandatory recall power específicamente changes el cost-benefit calculus de safety substantiation. Pre-MoCRA, gap in substantiation era theoretical risk. Post-MoCRA, gap can directly trigger forced product removal del mercado USA.

“Mandatory recall + records access + safety substantiation operan en tríada. Sin uno, los otros 2 fail. Con los 3, FDA tiene cascade enforcement capability nuevo.” — Camex · doctrina tríada MoCRA
▲ Impacto LatAm

LatAm exporters subject a potential mandatory recall ordering by FDA: significant operational change post-MoCRA. Pre-MoCRA: voluntary recall era discretional + manageable. Post-MoCRA: mandatory recall can override company preferences + force inmediato action. Los financial + reputational implications son comparables a foreign supplier de-listing. Defense: robust substantiation records + adverse event monitoring + recall plan formal documented.

✓ Acción Camex recomendada

Mandatory recall preparedness audit para LatAm cosmetics: (α) recall plan formal documented + tested, (β) communication tree pre-mapeada con USA importers + distributors, (γ) production records traceability hasta lot-level, (δ) safety substantiation records accessible + organized, (ε) mock recall exercise anual con measurable response time targets. Camex articula recall preparedness framework específico para LatAm.

Fuente: FDA Draft Guidance “Questions and Answers Regarding Mandatory Cosmetics Recalls” (18 dic 2025) · MoCRA Section 605-611 · 21 USC §364h

MoCRA tríada · 3 powers coordinadas
FDA ENFORCEMENT TRÍADA RECORDS ACCESS Section 605 + 610 SUBSTANTIATION Section 608 MANDATORY RECALL Section 611 CASCADE LOGIC α · Adverse event triggers attention β · FDA inicia inspection · records request γ · Substantiation records reviewed δ · Gaps + adulteration belief → mandatory recall CADA POWER REINFORCES LAS OTRAS 2
3 powers coordinadas en tríada. Cada uno reinforces los otros dos. Cascade automático: gap en substantiation puede trigger mandatory recall via records access.
04High-risk
FDA scrutiny list PFAS · asbestos · talc · others Active monitoring

FDA scrutiny list: 7 ingredients con elevated attention.

FDA está usando MoCRA authority para increase scrutiny de specific ingredients categorized as higher risk. La lista activa incluye: (α) PFAS (per- y polyfluoroalkyl substances) — Congress mandated FDA evaluation, dic 2024 FDA report published; (β) asbestos in talc-containing products — November 2025 proposed testing methods rule; (γ) formaldehyde + formaldehyde-releasers — banned for hair smoothing products; (δ) parabens — long-standing scrutiny + EU restrictions reference; (ε) phthalates — endocrine disruption concerns; (ζ) heavy metals (lead, cadmium, mercury) — particularly en color cosmetics; (η) 1,4-dioxane — contaminant en surfactant-containing products

Para LatAm cosmetics manufacturers, la lista tiene asymmetric exposure patterns: (i) PFAS afecta primarily long-wear/waterproof cosmetics (foundations, mascaras, eyeliners), (ii) asbestos/talc afecta any talc-containing product (baby powders, face powders, eyeshadows), (iii) formaldehyde-releasers afecta hair smoothing/relaxing products — categoría con high LatAm market presence, (iv) parabens + phthalates relevantes en preservative + fragrance systems, (v) heavy metals particularly relevant en color cosmetics + traditional/ethnic products, (vi) 1,4-dioxane relevante en sulfate-based cleansers. Cada manufacturer LatAm probablemente touches 2-4 de estos 7 en su product portfolio. Safety substantiation para products con scrutiny-list ingredients requires elevated documentation standard.

“FDA scrutiny list de 7 ingredients. Cada LatAm manufacturer probablemente touches 2-4 en portfolio. Para esos, substantiation requires elevated standard, no baseline.” — Camex · doctrina high-risk ingredients
▲ Impacto LatAm

LatAm manufacturers con products en categorías high-risk ingredient scrutiny: asymmetric exposure. Hair smoothing/relaxing products (Brasil, Caribe, Centroamérica markets) con formaldehyde-releasers son particularly exposed. Traditional/ethnic color cosmetics (México, Brasil, Centroamérica) con potential heavy metal contamination requires testing. Long-wear cosmetics con potential PFAS require ingredient verification. Cada categoría tiene specific substantiation requirements ahora elevated.

✓ Acción Camex recomendada

High-risk ingredient audit por product portfolio: identify products con scrutiny-list ingredients (PFAS, asbestos, formaldehyde, parabens, phthalates, heavy metals, 1,4-dioxane). For each: elevated substantiation documentation — testing data, supplier verification, alternative ingredient analysis si applicable, reformulation roadmap si pivotaje needed. Camex articula high-risk ingredient compliance específico.

Fuente: FDA PFAS Assessment Report (dic 2024) · Asbestos Testing Methods Proposed Rule (dic 2024 + withdrawal nov 2025) · MoCRA Section 612 · industry scrutiny tracking

7 ingredients · scrutiny matrix
LATAM SECTOR EXPOSURE PFAS long-wear Asbestos/talc powders/eyeshadows ★ Formaldehyde-rel. ★ hair smoothing Parabens preservatives Phthalates fragrance carriers ★ Heavy metals ★ color/traditional 1,4-dioxane sulfate cleansers ★ ELEVATED LATAM EXPOSURE Formaldehyde-releasers · Brasil + Caribe hair Heavy metals · color + ethnic cosmetics ★ EACH CATEGORY · ELEVATED SUBSTANTIATION Standard baseline insufficient
2 ingredients categories tienen elevated LatAm exposure: formaldehyde-releasers (hair smoothing) + heavy metals (color/traditional). Para esos, baseline substantiation insufficient.
05Litigation risk
Litigation exposure Plaintiffs’ bar Class action risk

El litigation risk vector: cuando substantiation gap = damages.

El second-order effect más under-discussed de MoCRA safety substantiation requirement: litigation exposure. Pre-MoCRA, plaintiffs’ bar tenía limited tools para attack cosmetic product safety claims — burden de proving harm + specific causation was high. Post-MoCRA, with adverse event reporting transparency + records access transparency, gaps en safety substantiation se vuelven evidence en class action litigation. La logic: si manufacturer no tenía adequate safety substantiation, that’s evidence of breach of duty of care + potential negligence theory.

Major plaintiffs’ law firms (Pritzker Hageman, Marler Clark, K&L Gates de defense side) ya están tracking adverse event reports + correlating con product safety claims. El framework operativo: (α) consumer reports adverse event, (β) plaintiffs’ attorney aggregates similar reports across consumers via online platforms, (γ) class action filed alleging breach of duty + inadequate substantiation, (δ) discovery requests target safety substantiation records, (ε) gaps en records become exhibit A in liability case. Para LatAm exporters: USA jurisdiction litigation is significantly more expensive + risky que LatAm jurisdiction. Defense cost alone for cosmetic class action $2M-10M+. Settlement potential $10M-100M+ for major class actions. Safety substantiation documentation is therefore not just regulatory compliance — es estructural litigation defense.

“Safety substantiation no es solo regulatory compliance — es litigation defense. Plaintiffs’ bar lee adverse event transparency now available. Gaps en substantiation become evidence.” — Camex · doctrina litigation vector
▲ Impacto LatAm

LatAm cosmetics exporters subject a USA jurisdiction class action exposure: structural risk asimétrico vs domestic operation. Multi-million dollar defense costs + settlement exposure + reputational damage. For LatAm SME exporters, single class action puede ser business-ending. Defense estructural: comprehensive safety substantiation + adverse event monitoring + recall plan formal. Insurance: USA product liability insurance coverage adequate (typically requires $5M-25M coverage for cosmetics serviendo USA market).

✓ Acción Camex recomendada

Litigation defense audit para LatAm cosmetics: (α) safety substantiation comprehensive contra los 6 pillars, (β) adverse event reporting system operational + documented, (γ) product liability insurance USA jurisdiction adequate, (δ) labeling + marketing claims supportable scientifically, (ε) ingredient supplier indemnification agreements. Camex coordinates con USA-side legal counsel + insurance brokers especializado en cosmetics LatAm.

Fuente: MoCRA litigation tracking · plaintiffs’ bar developments · class action filings post-MoCRA · USA product liability framework · Foley & Lardner analysis

Litigation · cascade post-MoCRA
LITIGATION CASCADE FRAMEWORK α · ADVERSE EVENT REPORT Consumer reports adverse event β · PLAINTIFFS’ BAR AGGREGATION Online platforms · pattern detection γ · CLASS ACTION FILED Breach of duty + inadequate substantiation δ · DISCOVERY REQUESTS Safety substantiation records subpoenaed ε · GAPS = EXHIBIT A Missing records become evidence SUBSTANTIATION = LITIGATION DEFENSE
5 steps litigation cascade post-MoCRA. Safety substantiation documentation = litigation defense, no solo regulatory compliance. Gaps become exhibit A.

6 pillars de safety substantiation evidence

Industry-converged standard · adequate substantiation

Cada pillar · su evidence · su weight.

Industry best practice framework
α
TOXICOLOGICAL

Per ingredient data

CIR Expert Panel reports, RIFM data para fragrance components, ECETOC para EU markets, CosIng database review. Each ingredient must have toxicological profile documented + safety margin calculated.

β
STABILITY

Product integrity

Accelerated stability testing (40°C/75% RH, 3 meses min) + real-time stability (full shelf life). Physical, chemical, microbiological stability documented. Color, odor, viscosity, pH tracked.

γ
MICROBIAL

Preservation efficacy

Challenge testing (USP <51> o equivalent) — inoculate product con specific organisms, verify kill kinetics. Preservative system efficacy demonstrated. Pertinent para water-containing products.

δ
COMPATIBILITY

Interactions tested

Ingredient interactions: chemical compatibility analysis. Packaging compatibility: migration testing si plastic/elastomer containers. Functional integrity throughout shelf life.

ε
★ CPSR

Formal safety report

Critical pillar más comúnmente missing. Cosmetic Product Safety Report by qualified safety assessor (toxicologist with credentials). Synthesizes los otros 5 pillars + formally concludes safety. EU framework reference.

ζ
INTENDED USE

Exposure assessment

Typical use patterns: frequency, amount, body area, rinse-off vs leave-on. Exposure calculations: skin contact, potential ingestion (lip products), inhalation (aerosols). User population characteristics.

7 ingredients · elevated FDA scrutiny

Active monitoring · LatAm exposure mapping

Cada ingredient · su scrutiny level · LatAm exposure.

FDA enforcement tracking
PFAS

Per- y polyfluoroalkyl substances

Congress mandated FDA evaluation. December 2024 FDA report published. Concern: bioaccumulation, environmental persistence. Found en long-wear/waterproof cosmetics primarily.

StatusFDA report 2024
Talc

Asbestos contamination

December 2024 proposed testing methods rule. November 2025 withdrawal. Concern: asbestos contamination en talc supply chain. Found en powders, eyeshadows, baby products.

StatusRule pending
HCHO-rel

Formaldehyde releasers · ★ LatAm

FDA banned formaldehyde in hair smoothing products. Concern: respiratory irritation, carcinogenicity. Hair smoothing/relaxing categoría con elevated LatAm market presence (Brasil, Caribe, Centroamérica).

StatusBAN active
Parabens

Preservative systems

Long-standing FDA scrutiny + EU restrictions reference. Concern: endocrine disruption. Multiple parabens (methyl, ethyl, propyl, butyl) con different scrutiny levels.

StatusScrutiny continua
Phthalates

Endocrine disruption

DEP, DBP, DEHP en fragrance carriers. Concern: reproductive toxicity. State-level restrictions (California Prop 65) ya in place.

StatusState + Federal
Metals

Heavy metals · ★ LatAm

Lead, cadmium, mercury, arsenic. Concern: chronic exposure toxicity. Particularly relevant en color cosmetics + traditional/ethnic products. LatAm color cosmetics + traditional products elevated exposure.

StatusTesting required
1,4-Dx

1,4-Dioxane contaminant

Contaminant en surfactant-containing products (shampoos, body washes). NY State + California specific restrictions. Mitigation: vacuum stripping.

StatusState restrictions

Records access powers · 605 vs 610 comparativo

Authority breakdown · operational implications

Cada section · su trigger · su scope.

FDA records access framework MoCRA
SECTION 605 · BASELINE
605
Adverse event records

Routine inspection authority. FDA may access adverse event report records durante routine inspection visits. Narrower scope. Pre-existing analog en food/drug systems.

TriggerRoutine inspection
ScopeAdverse event records
NoticeStandard inspection notice
FrequencyPer inspection schedule
SECTION 610 · ★ BROAD
610
Broad records access

Amplified power: FDA may access y copy records cuando reasonable belief de adulteration + serious adverse health consequences. Includes safety substantiation records.

TriggerReasonable belief adulteration
ScopeManufacturing + distribution + safety
NoticeInspection or written request
FrequencyAs needed by FDA

5 gaps comunes LatAm · safety substantiation

Lo que Camex articula closing

Los 5 gaps structural que LatAm typically tiene.

Camex defensive doctrine
α
CPSR MISSING

No formal safety assessor

Pillar ε typically missing. LatAm SME manufacturers operate sin formal Cosmetic Product Safety Report by qualified toxicologist. Closing: partnership con regulatory consultant + safety assessor.

β
STABILITY PARTIAL

Real-time stability missing

Pillar β typically partial. Accelerated stability done, real-time stability through shelf life not completed. Closing: extend stability program + retroactive documentation review.

γ
SUPPLIER DATA

Ingredient data dependency

Pillar α dependent on supplier-provided COAs only. CIR/RIFM/ECETOC consultation not done. Closing: independent ingredient research + supplier data validation.

δ
RECORDS SCATTERED

No centralized system

Records exist pero scattered en email, file servers, multiple personnel. No centralized system con search/retrieval. Closing: digital records management system + retrieval testing.

ε
USE EVALUATION

No exposure assessment

Pillar ζ typically missing. Quantitative exposure assessment based en typical use patterns not documented. Closing: formal exposure assessment per product.

★ INSIGHT CAMEX

Los 5 gaps son structural, not incidental. Cada uno representa LatAm operator practice anchored en pre-MoCRA reality. Closing requires sustained effort 6-12 meses, no quick fix. Total investment $30K-150K per product line dependiendo del scope + portfolio size. Vs single class action defense $2M-10M+ o single mandatory recall $500K-5M+. Cost-benefit overwhelmingly favorable. Camex articula gap closure framework integrado con renewal cycle (8 días) + GMP preparation (2027) + adverse event reporting + recall planning.

Section 608. 3 años sin guidance. 6 pillars. 5 gaps.

Safety substantiation es la obligation MoCRA más subestimada — y la más estructuralmente peligrosa para LatAm cosmetics manufacturers. Section 608 mandates “adequate substantiation” sin FDA guidance interpretativa después de 3+ años. La industria converged en 6 pillars de evidence standard. La mayoría LatAm operates con 2-4 pillars documented — gap structural de 2-3 pillars. Combined con FDA records access power (Section 605 + 610), mandatory recall authority, y litigation exposure post-MoCRA, los gaps se vuelven enforcement vectors materiales. Sem.6 día 2 cierra deep-dive Section 608. Próximas ediciones Sem.6: Adverse Event Reporting (mañana?), GMP Phase 2 preparation, sectorial specifics LatAm. Camex articula end-to-end MoCRA compliance para cosmetics LatAm.

32
Ediciones acumuladas en la serie
8 días
Hasta MoCRA renewal deadline
+ 200
Empresas articuladas con Camex
Camex · FDA Briefing · Sem.6 día 2 · Safety Substantiation Edición № 032 · 23.JUN.2026 · Próxima: 24.JUN.2026 Vol I · № 032

Leave A Comment

Your email address will not be published. Required fields are marked *

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.